This collection contains the scholarly publications from our current and past Presidents.

All items in the repository are protected by copyright; they may be used for educational purposes with proper attribution. All other uses require the author's permission.

Recent Submissions

  • Nonclassic congenital adrenal hyperplasia.

    Witchel, Selma Feldman; Azziz, Ricardo; Department of Obstetrics and Gynecology, Cedars-Sinai Medical Center, Los Angeles, CA; Department of Obstetrics and Gynecology, and Medicine, The David Geffen School of Medicine at UCLA, Los Angeles, CA (2010-07-30)
    Nonclassic congenital adrenal hyperplasia (NCAH) due to P450c21 (21-hydroxylase deficiency) is a common autosomal recessive disorder. This disorder is due to mutations in the CYP21A2 gene which is located at chromosome 6p21. The clinical features predominantly reflect androgen excess rather than adrenal insufficiency leading to an ascertainment bias favoring diagnosis in females. Treatment goals include normal linear growth velocity and "on-time" puberty in affected children. For adolescent and adult women, treatment goals include regularization of menses, prevention of progression of hirsutism, and fertility. This paper will review key aspects regarding pathophysiology, diagnosis, and treatment of NCAH.
  • Use of ethinylestradiol/drospirenone combination in patients with the polycystic ovary syndrome.

    Mathur, Ruchi; Levin, Olga; Azziz, Ricardo; Cedars-Sinai Medical Center, Los Angeles, CA (Dove Medical Press, 2008-08-27)
    Polycystic ovary syndrome (PCOS) is one of the most common endocrine/metabolic disorders found in women, affecting approximately 105 million women worldwide. It is characterized by ovulatory dysfunction, often presenting as oligomenorrhea or amenorrhea and either clinical or biochemical hyperandrogenism. Combined oral contraceptive (COC) therapy has long been a cornerstone of care for women with PCOS. COC therapy often provides clinical improvement in the areas of excessive hair growth, unpredictable menses, acne, and weight gain. One of the main issues in COC therapy is choosing the most appropriate progestin component to provide the greatest anti androgenic effects. Drospirenone, a relatively new progestin, has shown benefit in the PCOS population when used in conjunction with ethinyl estradiol. We now review the role of COCs in PCOS, focusing specifically on drospirenone. Controversy over metabolic effects of COCs in PCOS is also discussed.